Article Text

Download PDFPDF
Detection of subclinical atherosclerosis by electron beam tomography in females with heterozygous familial hypercholesterolaemia
  1. R D Santos1,2,
  2. R S Meneghelo2,
  3. A P M Chacra1,
  4. T L R Martinez1,
  5. J A Ramires1,
  6. J A M Carvalho2
  1. 1Lipid Clinic Heart Institute (InCor), University of Sao Paulo Medical School Hospital, Sao Paulo, Brazil
  2. 2Preventive Medicine Centre, Albert Einstein Hospital, Sao Paulo, Brazil
  1. Correspondence to:
    Dr Raul D Santos
    Unidade Clínica de Lipides- InCor HCFMUSP, Av. Dr Eneas C Aguiar 44, 2 andar anexo 2, Sao Paulo-SP 05403-000 Brazil;

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Familial hypercholesterolaemia (FH) is a common genetic disorder that affects around 1 in 500 people in its heterozygous form (HeFH). HeFH is associated with an early onset of coronary heart disease (CHD), especially in men.1 In women the risk of first CHD event is much less than in men, generally < 1% by 40 years of age, 12% by 50 years, 58% by 60 years, and 74% by 70 years of age. In spite of increased cholesterol values, the clinical expression of CHD in HeFH is variable and is also dependent on other risk factors. Currently there is consensus that males with HeFH should be treated early and aggressively with lipid lowering drugs. However, there is some controversy over when females with HeFH should be treated with statins since CHD generally manifests itself 10 years later than in men1 and there are restrictions to the use of statins in women during their reproductive years. Most importantly, cost effectiveness data on this issue are not available. Current CHD prevention guidelines recommend the use of clinical scores such as the Framingham risk charts in order to predict CHD risk and to guide pharmacological treatment.2 However, these scores were not developed for HeFH patients, therefore clinicians should rely empirically on plasma lipid concentrations, early CHD family history, and on the presence or absence of other CHD risk factors to institute treatment.

The detection of subclinical atherosclerosis could be helpful in determining selected subjects at high risk and therefore candidates for more aggressive and early lipid lowering.3,4 Coronary artery calcification (CAC), as determined by electron beam tomography, is a marker of coronary artery plaque burden. Severe CAC—that is, above the 75th centile for the population …

View Full Text